SOLID CANCER

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people with ovarian, peritoneal, or fallopian tube cancer that no longer responds to platinum chemotherapy. The drug is designed to target and kill cancer cells while sparing healthy ones. About 860 participants…

This early-phase trial tests a new treatment called TC-G203 for people with GPC3-positive solid tumors that have come back or spread after other treatments. The main goal is to find the safest dose and see if the therapy can shrink tumors. About 30 adults aged 18-75 who have not …

This study tests a tablet called PRaG-1 (made from cordycepin, a mushroom extract) in people who had solid tumors and now have low CD8+ immune cells after finishing radiation or chemotherapy at least six months ago. About 127 participants will take the tablet for two weeks, and t…

This early-stage study tests a new drug called AK138D1 in up to 200 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug may…

This study is testing a new way to manage care for 33 cancer patients who take oral chemotherapy at home. Instead of going to the hospital every month just to pick up medicine, a nurse will visit them at home twice in six months. An advanced practice nurse will coordinate everyth…

This study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A o…

This study looks at how gut bacteria affect immunotherapy in people with advanced solid tumors. It has two parts: first, finding bacterial markers linked to treatment response; second, testing if fecal transplants from healthy donors can make immunotherapy work better. About 60 a…